Skip to Main Content


In a 2019 study of 4744 patients with NYHA class II, III, IV heart failure and ejection fraction of less 40%, dapagliflozin (a sodium-glucose co-transporter 2 inhibitor) reduced the cumulative incidence of worsening heart failure or cardiovascular death.

In addition to their cardioprotective effects, the sodiumglucose linked transporter (SGLT) inhibitors, eg, canagliflozin and empagliflozin, slow progression of early diabetic nephropathy. Use of these agents may require reduction in diuretic dosing in those patients requiring natriuresis, and they should not be used in advanced chronic kidney disease.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.